



PRESS RELEASE

Opal Therapeutics Selected as Member of ARPA-H Investor Catalyst Hub Spoke Network

Opal Therapeutics Joins a Nationwide Network Working to Accelerate Transformative Health Solutions

SAN FRANCISCO, CA May 8th 2024 Opal Therapeutics, a company focused in drug discovery for women's health, announced today that it was selected as a spoke for the [Investor Catalyst Hub](#), a regional hub of [ARPANET-H](#), a nationwide health innovation network launched by the [Advanced Research Projects Agency for Health](#) (ARPA-H).

Based in the Greater Boston area and managed by [VentureWell](#), the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.

"We are delighted to announce Opal Therapeutics' inclusion in the Investor Catalyst Hub. Their focus on accelerating impactful biotechnologies to improve health aligns perfectly with our mission to enhance the quality of life for women across the globe. This opportunity significantly broadens our capabilities, enabling us to leverage new resources and insights to advance our research and development efforts more rapidly" – Morgan Stanton, CEO

Opal Therapeutics joins a [dynamic nationwide network of organizations](#) aligned to ARPA-H's overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.

"Our spoke network embodies a rich and representative range of perspectives and expertise," said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub. "Our spokes comprise a diverse network that will be instrumental in ensuring that equitable health solutions reach communities across every state and tribal nation."

As an Investor Catalyst Hub spoke, Opal Therapeutics gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library.

About Opal Therapeutics



Opal Therapeutics pioneers the development of non-hormonal therapies for chronic gynecological disorders, utilizing a groundbreaking platform that integrates female-focused biological research with advanced AI-driven drug discovery. Our mission is to explore and unlock innovative therapeutic opportunities in gynecology and reproductive medicine, enhancing the health and quality of life for women worldwide.

Website: opaltherapeutics.com

Contact: info@opaltherapeutics.com